Cancer is a devastating disease process that touches the lives of millions worldwide.
Despite advances in our understanding of the genomic architecture of cancers and the …

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers with a dismal
7% 5-year survival rate and is projected to become the second leading cause of cancer …

Cancer is associated with single or multiple gene defects. Recently, much research has
focused on incorporating genetic materials as one of the means to treat various types of …

Activating mutations in RAS family proteins are found in~ 25% of all human cancers.
Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten …

KRAS mutations are one of the most common oncogenic driver mutations in human cancers,
including non-small cell lung cancer (NSCLC), and have established roles in cancer …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal cancers with a dismal
prognosis for the patient. This is due to limited diagnostic options for the early detection of …

The safety and efficacy of tumor treatment are difficult problems to address. Recently,
lysosomes have become an important target for tumor treatment because of their special …

In our search for bioactive mushrooms native to British Columbia, we determined that the
ethanol extracts from fruiting bodies of the terrestrial polypore Albatrellus flettii had potent …

Metastasis remains the principle cause of mortality for breast cancer and presents a critical
challenge because secondary lesions are often refractory to conventional treatments. While …

RAS genes are the most commonly mutated in human cancers and play critical roles in
tumor initiation, progression, and drug resistance. Identification of targets that block RAS …